June 27, 2017 / 9:21 AM / 23 days ago

BRIEF-Glaxosmithkline starts phase III study for nasal polyps drug

1 Min Read

June 27 (Reuters) - Glaxosmithkline Plc:

* GSK starts phase III study with Mepolizumab in patients with nasal polyps

* Key secondary endpoint is time to first actual surgery for nasal polyps by week 52​

* Study is anticipated to complete in 2019

* Study will assess efficacy and safety of subcutaneous Mepolizumab 100mg compared to placebo Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below